Breaking News Instant updates and real-time market news.

PEIX

Pacific Ethanol

$1.89

-0.03 (-1.56%)

, GPRE

Green Plains

$17.62

0.12 (0.69%)

19:31
10/07/18
10/07
19:31
10/07/18
19:31

Fly Intel: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. President Trump is expected to announce the lifting of a federal ban on summer sales of higher-ethanol blends of gasoline on Tuesday ahead of a trip to Iowa the same day, according to Reuters, citing two sources familiar with the matter. The lifting of the summer ban on so-called E15 gasoline is expected to be coupled with restrictions on trading biofuel credits that underpin the program, sources said. Publicly traded companies in the space include Pacific Ethanol (PEIX) and Green Plains (GPRE). 2. Apple's (AAPL) top security officer told Congress that it had found no sign of suspicious transmissions or other evidence that it had been penetrated in a sophisticated attack on its supply chain, according to Reuters. Apple Vice President for Information Security George Stathakopoulos wrote in a letter to the Senate and House commerce committees that the company found no evidence for the main points in a Bloomberg Businessweek article published on Thursday, which said that chips inside servers sold to Apple by Super Micron Computer (SMCI) allowed for backdoor transmissions to China, the report added. 3. Barnes & Noble (BKS) is on the block, which means that investors and potential buyers will be perusing the bookseller more intensely, and should conclude that there are reams of opportunity in a company seen as a casualty of Amazon (AMZN), Andrew Bary wrote in this week's edition of Barron's. Shares of Barnes & Noble jumped 20% after the company announced it would evaluate "strategic alternatives," but even with that jump, there could be more upside in the shares because the company is valued cheaply relative to cash flow and sales, the report added. 4. Sony's (SNE) "Venom" debuted to $80M from 4,250 theaters in the U.S., easily the best showing ever for an October title. Overseas, the comic book movie soared to $125.2M from 58 markets for a global bow of $205.2M. "Venom" earned a B+ and sports 32% Rotten Tomatoes score. 5. MasterCard (MA), Eaton (ETN) and Terex (TEX) saw positive mentions in Barron's, while Western Union (WU) was mentioned cautiously.

PEIX

Pacific Ethanol

$1.89

-0.03 (-1.56%)

GPRE

Green Plains

$17.62

0.12 (0.69%)

AAPL

Apple

$224.26

-3.59 (-1.58%)

SMCI

Super Micro Computer

$0.00

(0.00%)

BKS

Barnes & Noble

$6.95

0.3 (4.51%)

AMZN

Amazon.com

$1,890.10

-18.9 (-0.99%)

SNE

Sony

$57.23

0.16 (0.28%)

MA

MasterCard

$213.19

-2.68 (-1.24%)

ETN

Eaton

$86.68

-0.98 (-1.12%)

TEX

Terex

$39.41

-0.68 (-1.70%)

WU

Western Union

$18.17

-0.43 (-2.31%)

  • 11

    Oct

  • 16

    Oct

  • 17

    Oct

  • 21

    Oct

  • 30

    Oct

  • 01

    Nov

PEIX Pacific Ethanol
$1.89

-0.03 (-1.56%)

11/28/17
RILY
11/28/17
INITIATION
Target $7
RILY
Buy
Pacific Ethanol initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Carter Driscoll started Pacific Ethanol with a Buy rating and $7 price target citing operational improvements and "healthier" industry dynamics.
10/03/18
CHLM
10/03/18
NO CHANGE
CHLM
Buy
Trump's potential waiver for year-round sale of E15 positive for industry, says Craig-Hallum
Commenting on indications that President Trump will ask the EPA next week to grant a waiver for the year-round sale of E15, Craig-Hallum analyst Eric Stine says he believes the chances are high that this will happen given the importance of the farm vote to midterm elections and Trump's re-election prospects. The analyst believes this would be a strong positive for the industry and would positively impact industry demand in 2019. Stine reiterates a Buy rating on Pacific Ethanol (PEIX) and Green Plains (GPRE) shares.
10/20/17
CHLM
10/20/17
NO CHANGE
CHLM
EPA commitment removes Pacific Ethanol, Green Plains overhang, says Craig-Hallum
Craig-Hallum analyst Eric Stine noted reports that EPA Commissioner Scott Pruitt has sent a letter to seven senators expressing his support for the Renewable Fuel Standard, which he sees supporting his belief that regulatory concerns are overblown. The analyst added that this news w removes a "sizable uncertainty for the industry" and an overhang for Pacific Ethanol (PEIX) and Green Plains (GPRE).
GPRE Green Plains
$17.62

0.12 (0.69%)

06/28/18
06/28/18
DOWNGRADE
Target $20

Equal Weight
Green Plains downgraded to Equal Weight with $20 price target at Stephens
As previously reported, Stephens analyst Farha Aslam downgraded Green Plains to Equal Weight from Overweight, stating that its restructuring plan is a long-term positive, but in the near-term the Company may be "forced to cut muscle." Also, Aslam believes the 18% rally over the last 6 months prices in much of the potential from Chinese purchases of U.S. ethanol, she tells investors. The analyst lowered her price target on Green Plains shares to $20 from $32.
06/28/18
06/28/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AeroVironment (AVAV) downgraded to Hold from Buy at Stifel with analyst Joseph DeNardi citing valuation, but he continues to maintain a positive bias on the stock. 2. Beacon Roofing (BECN) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Eisen saying he sees a threat to consensus estimates based on the higher oil price and freight costs amid declining industry demand. 3. Green Plains (GPRE) downgraded to Equal Weight from Overweight at Stephens with analyst Farha Aslam stating that its restructuring plan is a long-term positive, but in the near-term the company may be "forced to cut muscle." 4. Mattel (MAT) downgraded to Underperform from Neutral at DA Davidson with analyst Linda Bolton Weiser noting that the stock price has risen 29% from its April low even though the company's fundamentals have not improved. 5. Aquinox (AQXP) downgraded to Hold from Buy at Needham with analyst Alan Carr noting that the company's Phase 3 trial of rosiptor in Interstitial Cyrstitis failed to demonstrate efficacy, with no evidence of activity at any point or within any subset of patient subset. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here
07/31/18
ROTH
07/31/18
NO CHANGE
Target $25
ROTH
Buy
Roth Capital sees selloff in Green Plains as overdone
Roth Capital analyst Craig Irwin sees the selloff in Green Plains as overdone, as ethanol has the clear support of President Trump, and positive policy changes are likely to materialize at some point this year. Short-term volatility with corn prices pressured on trade tensions with China likely benefits Ethanol profits in 2H18, he adds. The analyst reiterates a Buy rating and $25 price target on the shares.
AAPL Apple
$224.26

-3.59 (-1.58%)

10/04/18
KEYB
10/04/18
NO CHANGE
KEYB
Carrier survey indicates healthy start for Apple iPhone XS, says KeyBanc
KeyBanc analyst John Vinh says his initial round of carrier survey for the current Apple (AAPL) iPhone XS cycle indicates "solid" sell-through for the iPhone XS/Max as inventories are lean post launch. Demand for the iPhone XS Max has been the strongest, with the majority of stores being sold out, while inventories for the iPhone XS are very healthy, he adds. The analyst also notes that demand for the new models appear to be better compared to the iPhone 8/X launch last year, driven mainly by the adoption of a larger screen at iPhone XS Max. Additionally, Vinh is encouraged with the robust results despite limited promotional activity. His favorite Apple supply chain names are Broadcom (AVGO), Qorvo (QRVO), Skyworks (SWKS), and Synaptics (SYNA).
10/01/18
PIPR
10/01/18
NO CHANGE
Target $250
PIPR
Overweight
Piper calls iPhone ASP estimate conservative after iPhone user survey
After surveying over 700 domestic iPhone owners to ask which iPhone they would buy if they were to upgrade this year, Piper Jaffray analyst Michael Olson believes the consensus average selling price estimate may be conservative. Of those surveyed, 39% indicated they would buy one of the two "flagship" devices, the iPhone Xs or Xs Max, while the remaining 61% would buy some combination of iPhone Xr, 8 or 7, Olson tells investors in a research note. The analyst now expects a fiscal 2019 average selling price of $770, above his previous estimate of $758. Further, Olson believes more choices for next gen form factor iPhones will drive unit upside relative to consensus. For fiscal 2019 he models 223M units versus the consensus at 218M. The analyst raised his estimates for Apple and continues to recommend owning the shares with an Overweight rating and $250 price target.
09/28/18
NOMU
09/28/18
NO CHANGE
Target $215
NOMU
Buy
Apple price target raised to $215 from $210 at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal raised his price target for Apple to $215 while keeping a Neutral rating on the shares. Falling shipment times for the XS models lifts visibility into the trajectory of two of the three new phones, Kvaal tells investors in a research note. Further, longer shipment times for the Max than the XS imply a "material" average selling price boost, the analyst contends. He upped his fiscal 2019 earnings per share estimate to $14.35 from $14.16.
10/01/18
NOMU
10/01/18
NO CHANGE
NOMU
Buy
ITC ruling Friday reinforces Qualcomm's momentum, says Nomura Instinet
Nomura Instinet analyst Romit Shah believes Friday's International Trade Commission ruling reinforces Qualcomm's (QCOM) momentum in the Apple (AAPL) litigation and increases the likelihood the dispute will be settled before the end of the year. The analyst says he's been recommending Qualcomm shares on the belief that the Apple dispute would be resolved by the end of the year and Qualcomm stands to "benefit greatly" from a resolution. Shah keeps a Buy rating on the shares with an $80 price target.
SMCI Super Micro Computer
$0.00

(0.00%)

08/22/18
DADA
08/22/18
NO CHANGE
Target $14
DADA
Neutral
Super Micro Computer price target lowered to $14 from $24 at DA Davidson
DA Davidson analyst Mark Kelleher lowered his price target on Super Micro Computer to $14 and kept his Neutral rating despite the Q4 earnings beat, citing the company's continued "accounting issues and imminent delisting". The analyst states that the "likely suspension" of trading on the Nasdaq will take Super Micro to be quoted on the OTC, even though the company claims to be making "significant progress" toward filing its delinquent reports and believes its cash flows have not been impacted by the audit committee investigation in its 10K filing.
10/05/18
MAXM
10/05/18
DOWNGRADE
MAXM
Hold
Super Micro Computer downgraded to Hold from Buy at Maxim
10/05/18
MAXM
10/05/18
DOWNGRADE
MAXM
Hold
Super Micro Computer downgraded to Hold at Maxim
As reported earlier, Maxim analyst Nehal Chokshi downgraded Super Micro Computer to Hold. The analyst states that while the Bloomberg Businessweek article alleging the company's "servers sold to customers contained malicious microchips" were strongly refuted, the detail, the reputable nature of the source, and the number of cross reference checks lend to its credibility. Chokshi further notes that the company's ongoing delay in releasing its 2017 10K filing adds to his concerns, stating that he no longer sees reward relative to risk as asymmetric.
10/05/18
10/05/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. HP CUT TO NEUTRAL AT JPMORGAN: JPMorgan analyst Paul Coster downgraded HP Inc. (HPQ) to Neutral from Overweight while raising his price target for the shares to $29 from $28. Despite the company's "excellent execution," the shares have limited catalysts ahead, Coster told investors in a research note following the company's analyst day. The analyst recommended investors take profits with the stock up 24% year-to-date. HP shares were lower by 1.9% to $25.91 in late morning trading. ELI LILLY UPGRADED TO OUTPERFORM AT BMO: BMO Capital analyst Alex Arfaei upgraded Eli Lilly (LLY) to Outperform from Market Perform and raised his price target on the shares to $130 from $107. The analyst cited the prospects of LY3298176, a GIP and GLP-1 dual receptor agonist presented at EASD 54th Annual Meeting, which he believes "meaningfully improves" the company's long-term growth prospects. Arfaei sees "continued strong growth of the GLP-1 class" and anticipates an annualized revenue growth of about 15% through 2027, adding that he is also positive on Eli Lilly's margins and its other indications in fields such as obesity. Eli Lilly shares were higher by 1.8% to $115.01 in late morning trading. PEPSI CUT TO NEUTRAL AT MACQUARIE: Macquarie analyst Caroline Levy downgraded Pepsi (PEP) to Neutral from Outperform and cut its price target to $107 from $122 following the company's Q3 report. Levy noted that Pepsi reported solid Q3 organic sales growth of 5%, but EBIT margins fell do to increased brand spending, higher input costs abroad due to FX hikes, and higher freight. The analyst said she expects these pressures to remain a drag on margins and cut estimates to reflect dilution from the Sodastream acquisition, tougher comps, and lack of tax reform benefits. Further, Levy expects organic sales growth will require more investment while costs continue to climb. ROKU STARTED WITH A NEUTRAL AT WEDBUSH: Wedbush analyst Michael Pachter initiated Roku (ROKU) with a Neutral rating and $73 price target. While Roku has built an "exceptional" platform on the back of its players and is positioning itself as the best-in-class option for OTT advertising, Roku's growth is fully priced into its share price, Pachter told investors in a research note. The analyst believes that any pullback may provide an opportunity to build a position. SUPER MICRO COMPUTER CUT TO HOLD AT MAXIM: Maxim analyst Nehal Chokshi downgraded Super Micro Computer (SMCI) to Hold from Buy. The analyst stated that while the Bloomberg Businessweek article alleging the company's "servers sold to customers contained malicious microchips" were strongly refuted, the detail, the reputable nature of the source, and the number of cross reference checks lend to its credibility. Chokshi further noted that the company's ongoing delay in releasing its 2017 10K filing adds to his concerns, stating that he no longer sees reward relative to risk as asymmetric. Super Micro Computer shares were higher by 3.1% to $12.99 in late morning trading.
BKS Barnes & Noble
$6.95

0.3 (4.51%)

12/01/17
CHLM
12/01/17
DOWNGRADE
CHLM
Hold
Barnes & Noble downgraded to Hold from Buy at Craig-Hallum
12/01/17
12/01/17
DOWNGRADE
Target $8

Hold
Barnes & Noble downgraded to Hold following revenue miss at Craig-Hallum
As previously reported, Craig-Hallum analyst Alex Fuhrman downgraded Barnes & Noble to Hold from Buy after the company's Q2 revenue missed expectations, saying that its reiterated 2018 EBITDA guidance is now more dependent on a second half improvement and cost cuts. The analyst, who thinks weak top-line growth is likely to continue for the foreseeable future, cut his price target on B&N shares to $8 from $15.
12/01/17
12/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Priceline (PCLN) downgraded to Hold from Buy at Argus with analyst John Staszak downgraded Priceline (PCLN) saying shares are fairly valued around the current price level of $1,740 as the stock trades near the high-end of its five-year PE range. 2. Cummins (CMI) downgraded to Neutral from Buy at Goldman Sachs with analyst Jerry Revich saying to position for the next leg of the Machinery recovery, he prefers exposure to agriculture over trucks. 3. VMware (VMW) was downgraded to Hold from Buy at Gabelli and Drexel Hamilton. 4. Barnes & Noble (BKS) downgraded to Hold from Buy at Craig-Hallum with Alex Fuhrman citing the company's second quarter revenue miss. 5. Regeneron (REGN) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying she believes the competitive threat from Novartis' (NVS) vision-loss drug RTH258 is being underappreciated by the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/07/18
GABE
09/07/18
UPGRADE
Target $10
GABE
Buy
Barnes & Noble upgraded to Buy from Hold at Gabelli
AMZN Amazon.com
$1,890.10

-18.9 (-0.99%)

10/03/18
STFL
10/03/18
NO CHANGE
Target $155
STFL
Buy
Trade Desk pullback due to misplaced concerns about Amazon, says Stifel
Stifel analyst John Egbert raised his mid- and long-term estimates for Trade Desk (TTD) citing momentum from new advertiser wins and the fact that platform spend and attach rates are benefiting from the recent New Wave product launch. He believes recent weakness in Trade Desk shares may be related to worries over online reports suggesting Amazon (AMZN) has discussed building a proprietary video ad serving product for its own streaming business, but sees these concerns as misplaced, Egbert added. Based on the available information, it seems like Amazon is focusing on video ad server technology, not a connected TV ad buying software tool, which would pit it against Trade Desk partners Comcast's (CMCSA) Freewheel and Google (GOOGL) Ad Manager, not Trade Desk itself, Egbert explains. He maintains a Buy rating on Trade Desk and raised his price target on the stock to $155 from $130.
10/04/18
DADA
10/04/18
UPGRADE
Target $27
DADA
Buy
Cloudera upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Rishi Jaluria upgraded Cloudera (CLDR) to Buy from Neutral and raised his price target to $27 from $15 while also affirming Hortonworks (HDP) at Buy and raising its price target to $35 from $24 after the two companies announced an all-stock merger of equals yesterday. The analyst is positive on the merger's ability to reduce pricing pressure from the separation from the other Hadoop vendors, equip Cloudera to battle cloud data warehouse vendors like AWS (AMZN) Redshift, and accelerate innovation. Jaluria adds that even after the aftermarket gains in both companies' stocks, the market is likely undervaluing the combined company by assigning a 5-times enterprise value to expected forward revenue multiple, which is a "significant discount" to the peer group.
10/04/18
DADA
10/04/18
NO CHANGE
Target $2450
DADA
Buy
Amazon.com minimum wage increase a positive, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $2,450 price target on Amazon after its decision to increase its minimum wage to $15 per hour starting November 1st. The analyst views the move as a positive in helping the company to attract talent as a way to sustain its growth, to require more employees at the minimum wage level as it expands its physical footprint with Amazon Go stores / book stores / and Whole Foods businesses, and to improve its "political influence" by paying a "living wage". Forte also sees the expected mid-single digit payroll increase as a result of the change to have limited impact financially as it will likely be accompanied by eliminated incentive pay and because of its reliance on "base-light, stock-heavy" compensation strategy.
10/05/18
RHCO
10/05/18
NO CHANGE
RHCO
Buy
Amazon's Accelerator Program can 'broaden the moat' in retail, says SunTrust
SunTrust analyst Youssef Squali is positive on the CNBC-reported launch of Accelerator Program for exclusive brands at Amazon with the intention of signing up manufacturers looking to create made-for-Amazon products. The analyst notes that the program would feature "marketing support and tools that track performance and feedback" that could be applied to any retail category. Squali believes that the offering would broaden Amazon's moat in retail, serving as an "extension of its growing suite of private label brands" while contributing to the company's product selection at "great prices". Squali has a Buy rating on Amazon.
SNE Sony
$57.23

0.16 (0.28%)

09/10/18
FBCO
09/10/18
UPGRADE
FBCO
Outperform
Sony upgraded to Outperform from Neutral at Credit Suisse
06/20/18
PIPR
06/20/18
NO CHANGE
PIPR
May NPD video game software sales rose 15%, says Piper Jaffray
May NPD video game software sales were up 15% year-over-year, driven by Sony (SNE) and Nintendo (NTDOY) launches of first-party titles, Piper Jaffray analyst Michael Olson tells investors in a research note. The analyst views May NPD data as less relevant for publishers since there were no major launches from Activision Blizzard (ATVI), Electronic Arts (EA) or Take-Two (TTWO). He maintains Overweight ratings on all three names.
05/07/18
UBSW
05/07/18
DOWNGRADE
UBSW
Neutral
Sony downgraded to Neutral from Buy at UBS
04/20/18
PIPR
04/20/18
NO CHANGE
PIPR
March NPD video game software sales fell 25%, says Piper Jaffray
March NPD video game software sales declined 25% year-over-year due to a tough compare with the launch of Nintendo's (NTDOY) Switch console a year ago and its highly successful launch title, The Legend of Zelda, Piper Jaffray analyst Michael Olson tells investors in a research note. The top two titles in the month were Ubisoft's Far Cry 5 and Sony's (SNE) MLB: The Show, but combined, the two generated less revenue than last year's Zelda, Olson adds. He views this month's data as less relevant given the absence of a major launch from Activision Blizzard (ATVI), Electronic Arts (EA) or Take-Two (TTWO). However, Olson thinks the March NPD data is most positive for Activision and least favorable for EA, which he says faced difficult compares to the launch of Mass Affect: Andromeda the prior year. The analyst keeps Overweight ratings on Activision, EA and Take-Two.
MA MasterCard
$213.19

-2.68 (-1.24%)

09/26/18
BMOC
09/26/18
INITIATION
Target $238
BMOC
Outperform
MasterCard initiated with an Outperform at BMO Capital
Target $238.
10/02/18
WELS
10/02/18
NO CHANGE
Target $150
WELS
Outperform
Euronet price target raised to $150 from $120 at Wells Fargo
Wells Fargo analyst Timothy Willi raised his price target for Euronet (EEFT) to $150 from $120 following the Visa (V) decision to permit Dynamic Currency Conversion transactions globally. The analyst estimates that Visa non-EU DCC revenue should contribute roughly $200M in incremental revenue during 2019, and believes that ultimately the ability to derive DCC revenues globally from Visa in addition to MasterCard (MA) will provide an incremental tailwind for Euronet and the ability to grow its ATM footprint at a pace that maybe faster than previously contemplated. Willi reiterates an Outperform rating on Euronet shares.
10/01/18
WELS
10/01/18
NO CHANGE
Target $250
WELS
Outperform
MasterCard price target raised to $250 from $230 at Wells Fargo
Wells Fargo analyst Donald Fandetti raised his price target for MasterCard to $250 from $230 as he expects another solid quarter and a revenue/EPS beat seems likely. The analyst believes global spend trends remain healthy, and gas/inflation are tailwinds. Fandetti reiterates an Outperform rating on the shares.
09/26/18
BMOC
09/26/18
INITIATION
Target $238
BMOC
Outperform
MasterCard initiated with an Outperform at BMO Capital
As reported earlier, BMO Capital analyst James Fotheringham initiated MasterCard with an Outperform rating and a price target of $238. The analyst says the company's current "full" valuation is keeping him from assigning a Top Pick rating, but he sees its business model offering "above average" potential to surprise positively on revenue growth thanks to the company's exposure to "fast-growing international markets, B2B payment flows, and cross-border volumes".
ETN Eaton
$86.68

-0.98 (-1.12%)

08/17/18
JPMS
08/17/18
NO CHANGE
JPMS
Class 8 Retails sales up 27% year-over-year, says JPMorgan
JPMorgan analyst Ann Duignan said ACT Research reported North American Class 8 retail sales of 25,839 units in July, up 27% year-over-year. Net orders were 52,629 units, representing the strongest monthly orders on record, and builds were 31,039 units, Duignan wrote in a note to investors.
09/06/18
JPMS
09/06/18
NO CHANGE
JPMS
Class 8 truck orders set all-time record in August, says JPMorgan
Class 8 net orders in August were 53,100 units, up 150% year-over-year and up 1% month-over-month, setting a new all-time record, JPMorgan analyst Ann Duignan tells investors in a research note, citing ACT Research. Class 5-7 July net orders were 23,700 units, up 26% year-over-year and up 18% month-over-month, the analyst adds. She says truck orders have the largest incremental impact on Navistar (NAV), Paccar (PCAR), Cummins (CMI), Eaton (ETN) and Allison Transmission (ALSN).
08/20/18
MSCO
08/20/18
INITIATION
Target $86
MSCO
Equal Weight
Eaton initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Joshua Pokrzywinski initiated Eaton with an Equal Weight rating and a price target of $86. The analyst notes that while the company is well positioned in the near term with its persisting short-cycle strength in Electrical Products and Hydraulics, the bulls may be disappointed in 2019 as Eaton's restructuring savings taper off and its operating leverage returns to its "modest historical levels".
09/21/18
UBSW
09/21/18
UPGRADE
Target $100
UBSW
Buy
Eaton upgraded to Buy from Neutral at UBS
UBS analyst Steven Winoker upgraded Eaton to Buy and raised his price target for the shares to $100 from $91. The analyst sees "growth momentum" adding to the company's "already strong margin and balance sheet story." Further, his firm's employee review analysis shows "material year on year improvement." After lagging peers, Eaton's growth has now improved to in-line or better, Winoker tells investors in a research note. The analyst also expects the company's margins to reach higher levels through the cycle.
TEX Terex
$39.41

-0.68 (-1.70%)

08/20/18
BARD
08/20/18
UPGRADE
Target $38
BARD
Neutral
Terex upgraded to Neutral at Baird
As reported previously, Baird analyst Mig Dobre upgraded Terex to Neutral from Underperform. The analyst cited its recent pullback and multiple compression as well as its upcoming investors day. Dobre maintained his $38 price target on Terex shares.
09/05/18
DBAB
09/05/18
INITIATION
Target $34
DBAB
Sell
Terex resmed with a Sell at Deutsche Bank
Deutsche Bank analyst Chad Dillard resumed coverage of Terex with a Sell rating and $34 price target. Since late cycle concerns took hold in April, the Machinery sector has underperformed the S&P 500 by 15% and is approaching valuation lows last seen during the 2015 energy and 2008 global financial crises, Dillard tells investors in a research note. He resumed coverage of eight stocks in the Machinery sector, with two Buy ratings, one Sell rating and five Holds.
08/20/18
08/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Positive from Neutral at Susquehanna and to Overweight from Neutral at Piper Jaffray. 2. Qualcomm (QCOM) upgraded to Buy from Neutral at Rosenblatt with analyst Jun Zhang citing benefits from 5G smartphone growth over the next few years. 3. Flir Systems (FLIR) upgraded to Outperform from Market Perform at William Blair with analyst Louie DiPalma he believes, in the near-term, Flir's enhanced automation and software capabilities are rendering its sensors more powerful and driving adoption. Additionally, DiPalma believes thermal sensors will be common in autonomous vehicles over the longer term, which could be a major source of long-term upside. 4. RBS (RBS) upgraded to Buy from Neutral at Citi. 5. Terex (TEX) upgraded to Neutral from Underperform at Baird with analyst Mig Dobre citing its recent pullback and multiple compression as well as its upcoming investors day. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/22/18
UBSW
08/22/18
NO CHANGE
Target $52
UBSW
Buy
Terex sees continued growth in AWP market, says UBS
UBS analyst Steven Fisher met with Terex management who reiterated they are confident in demand growth from 2018-2023 and that they will get their share of the rising market. The analyst noted bears believe the AWP market is set to peak and rollover, but management expects industry revenues to grow at an upper single digit through 2023. Fisher reiterated his Buy rating and $52 price target on Terex shares.
WU Western Union
$18.17

-0.43 (-2.31%)

02/14/18
MZHO
02/14/18
UPGRADE
MZHO
Neutral
Western Union upgraded to Neutral from Underperform at Mizuho
09/27/18
DBAB
09/27/18
NO CHANGE
DBAB
Buy
FleetCor could be acquirer of Western Union's B2B business, says Deutsche Bank
Bloomberg yesterday reported that Western Union (WU) is working with an adviser to potentially sell its business-to-business cross-border payments business, and that the unit could fetch $500M. Deutsche Bank analyst Ashish Sabadra believes FleetCor (FLT) could be a potential acquirer given the synergies with its Cambridge B2B cross-border payments. The analyst estimates an acquisition could be $1 accretive to earnings per share 12-18 months post acquisition close, depending on the terms of a deal and the margin potential. More importantly, the deal would significantly enhance FleetCor's market positioning in B2B cross-border payments, Sabadra tells investors in a research note. The analyst thinks a potential accretive acquisition could provide upside to 2019 estimates. He keeps a Buy rating on FleetCor.
07/19/18
MSCO
07/19/18
NO CHANGE
MSCO
Morgan Stanley upgrades Payments and Processing industry to Attractive
Morgan Stanley analyst James Faucette upgraded his view of the Payments and Processing industry to Attractive, citing the firm's U.S. Strategy Team's call for rotation out of Technology and his view that Payments will be seen as an attractive option for investors looking to become more defensive. Investors underappreciate the resilience of consumer spending and Faucette sees the potential for his Payments coverage market-cap weighted earnings growth to accelerate organically to 15% over 2018-2020 from 11% growth over the last three years, he tells investors. In the group, the firm has Overweight ratings on Visa (V), MasterCard (MA), PayPal (PYPL), GreenSky (GSKY), Worldpay (WP) and FleetCor (FLT). Morgan Stanley has Underweight ratings on Western Union (WU) and On Deck Capital (ONDK), having downgraded On Deck this morning.
07/17/18
WOLF
07/17/18
INITIATION
Target $20
WOLF
Underperform
Western Union initiated with an Underperform at Wolfe Research
Wolfe Research analyst Darrin Peller started Western Union with a Underperform rating and $20 price target.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
Morgan Stanley China hardware analyst to hold analyst/industry conference call »

China Hardware Tech…

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

BABA

Alibaba

$142.90

1.1 (0.78%)

, TCEHY

Tencent

$0.00

(0.00%)

12:17
10/20/18
10/20
12:17
10/20/18
12:17
Periodicals
Chinese internet giants down, not out, Barron's says »

Alibaba (BABA), Tencent…

BABA

Alibaba

$142.90

1.1 (0.78%)

TCEHY

Tencent

$0.00

(0.00%)

BIDU

Baidu

$191.93

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 02

    Nov

BLK

BlackRock

$401.61

1.74 (0.44%)

, IVZ

Invesco

$22.00

0.74 (3.48%)

12:13
10/20/18
10/20
12:13
10/20/18
12:13
Periodicals
Fund companies sued by own employees over pricey 401k plans, Barron's says »

BlackRock (BLK),…

BLK

BlackRock

$401.61

1.74 (0.44%)

IVZ

Invesco

$22.00

0.74 (3.48%)

TROW

T. Rowe Price

$100.13

0.31 (0.31%)

SCHW

Charles Schwab

$46.81

0.11 (0.24%)

MTB

M&T Bank

$162.72

2.09 (1.30%)

MS

Morgan Stanley

$46.43

0.4 (0.87%)

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

, BLK

BlackRock

$401.61

1.74 (0.44%)

12:04
10/20/18
10/20
12:04
10/20/18
12:04
Periodicals
Khashoggi case puts financial ties to Saudis under strain, Barron's says »

The suspected killing of…

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

BLK

BlackRock

$401.61

1.74 (0.44%)

BX

Blackstone

$34.66

-0.61 (-1.73%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

IMAX

Imax

$22.45

-0.11 (-0.49%)

SIX

Six Flags

$66.40

-1.16 (-1.72%)

WWE

WWE

$82.02

-1.49 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 13

    Nov

  • 14

    Nov

  • 26

    Feb

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.